During the past decade, Helsingin Reumakeskus Oy conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Helsingin Reumakeskus Oy" are "Arthritis, Rheumatoid" (1 trials) and "Psoriatic Arthritis" (1 trials). Many other conditions were trialed in "Helsingin Reumakeskus Oy" in a lesser frequency.

Most popular intervention types in "Helsingin Reumakeskus Oy" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Apremilast 20mg" (1 trials), "Apremilast 30mg" (1 trials), "CP-690,550" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Helsingin Reumakeskus Oy" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Helsingin Reumakeskus Oy". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Helsingin Reumakeskus Oy, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Helsingin Reumakeskus Oy, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".